Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 61 to 70 of 302

TitleReference numberPublishedLast updated
Signatera for detecting molecular residual disease from solid tumour cancersMIB307
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancerTA823
Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomasCG118
Contrast-enhanced spectral mammography for breast cancerMIB304
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapiesTA819
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancerTA816
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrenceTA817
Stockholm3 for prostate cancer screeningMIB303
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancerTA812
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrenceTA810

Results per page

  1. 10
  2. 25
  3. 50
  4. All